Partial lottery funding for good proposals in under-funded cancers
Once a proposal in a neglected cancer passes a quality bar, pick winners by lottery instead of by tiny differences in review scores, which mostly reflect fashion.
Reviewer scores in the middle of the distribution are nearly random and are known to favour established fields and safe applicants. For pancreatic, oesophageal, glioblastoma, sarcoma, mesothelioma and other neglected cancers, a funder would run a two-stage process: a rigorous pass/fail quality gate, then random selection among passes. This removes fashion bias, lowers the cost of applying and reviewing, and makes it easier to enter a new field.
- Funding follows fashion, not burden · Money goes to the cancers and questions that are easy or popular, not the ones that kill most or where a dollar would do most.
Pages like this
not linked directly; found by shared links- IdeaCure-focused prizes: pay for verified long-term cures, not for drugs
Shares Funding follows fashion, not burden, Glioma & glioblastoma, Pancreatic ductal adenocarcinoma.
- IdeaOpen-source drug discovery to clinical proof of concept for neglected cancers
Shares Funding follows fashion, not burden, Oesophageal cancer, Sarcomas (soft tissue, bone, GIST).
- IdeaOne legal framework for pooling rare cancer data across borders
- PersonRandy Pausch
Shares Funding follows fashion, not burden, Pancreatic ductal adenocarcinoma.
- PersonPeter W. T. Pisters
Shares Sarcomas (soft tissue, bone, GIST), Pancreatic ductal adenocarcinoma.
- PersonTerry Fox
Shares Funding follows fashion, not burden, Sarcomas (soft tissue, bone, GIST).
- IdeaPay a prize for rare cancer drugs instead of hoping for a market
Shares Funding follows fashion, not burden, Sarcomas (soft tissue, bone, GIST).
- IdeaA guaranteed purchase prize for the first drug against a named hard target
Shares Funding follows fashion, not burden, Pancreatic ductal adenocarcinoma.